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See Article, pages 640–646Current treatment of hepatitis B has been facilitated
with the advent of oral nucleoside analogues. These
agents, at least in the short to medium term are generally
safe drugs, given once daily, orally, usually with minimal
toxicity. Chronic hepatitis B is a prolonged illness how-
ever, and the long-term eﬃcacy and toxicity of oral
nucleoside analogues remains unknown. Buti and co-
authors in an analysis published in this issue of the Jour-
nal [1], review the cost-eﬀectiveness of current nucleo-
side analogue therapy. The analysis is the result of
collaboration between hepatologists, a health economist
and Gilead Sciences. Their model has not included PEG
interferon treatment, mainly because of reliance in the
model on the assumption that the level of HBV DNA
used to deﬁne virological response is higher than for oral
antivirals [2]. This assumption would be disputed by
some [3].
Lamivudine followed by adefovir after the onset of
resistance has been the most widely applied nucleoside
treatment option; this strategy has been shown to be
cost-eﬀective, even though it is now no longer consid-
ered clinically appropriate in many regions to begin lam-
ivudine monotherapy for patients with high levels of
HBV replication given the risk of multi-drug resistant
hepatitis B and that fact that more potent agents with
lower rates of resistance are available [4]. Recent guide-
lines have attempted to simplify and importantly opti-
mise nucleoside analogue use. However these
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analysis usefully evaluates the cost-eﬀectiveness of ten-
ofovir, entecavir and telbivudine, all relatively recently
approved potent nucleoside reverse transcriptase inhibi-
tors active against hepatitis B virus.
In their analysis, the authors employed a Markov
model used to project lifetime complications and costs
in a cohort of 40 year old chronic hepatitis B patients.
Both HBeAg positive and negative patients were eval-
uated, adjudging the annual probability of moving
from one disease state, such as chronic hepatitis to cir-
rhosis. Short-term virological response rates have been
established in controlled clinical trials, and these were
utilized in this model. The authors used a ‘‘virological
response” i.e. suppression of HBV DNA to less than
300 or 400 copies/ml serum as an index of disease mod-
iﬁcation. It is noteworthy that a somewhat absolute
assumption was utilized. It is likely that a gradation
of histological improvement (itself used as a surrogate
for modiﬁcation of the natural history of the disease)
occurs with lesser degrees of HBV suppression [6–8].
However more profound viral suppression is associated
with less risk of resistance, other factors being equal. In
the model, treatment was discontinued after HBeAg
seroconversion, although the durability of this alter-
ation has not been fully established in diﬀerent ethnic
groups or for diﬀerent HBV genotypes. The model
did not take into account loss of HBsAg, the ideal
endpoint of nucleoside (or interferon) treatment [9,10].
Treatment was applied indeﬁnitely in HBeAg-negative
patients.
For modeling several assumptions are required. Pro-
gression rates were assumed based on available natural
history data. All models are likely to be sensitive to these
assumptions. The authors have not, for example, taken
into account the impact of the rate of progression ofean Association for the Study of the Liver.
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crucial. The authors used cost data derived from the
Spanish Health Care System.
Six diﬀerent strategies were compared, including no
treatment, or treatment with lamivudine, adefovir, ente-
cavir, telbivudine, and tenofovir. ‘De novo’ combination
treatments, particularly with lamivudine and adefovir
were not compared. For resistance, a rescue therapy
was recommended as resistance likely compromises the
outcome of treatment. Non-responders and patients
with resistance were treated according to the current
EASL recommendations. In particular two combina-
tions were considered for the management of resistance:
a rescue therapy with lamivudine and adefovir, or alter-
natively with tenofovir combined with entecavir. The
authors did not consider the addition of tenofovir for
lamivudine resistance. This may have been revealing,
as the eﬃcacy of adefovir and lamivudine salvage ther-
apy for lamivudine or adefovir resistance is partly
dependent upon the concentration of HBV DNA at
the time of additional therapy, and on the presence of
speciﬁc substitutions – for example the addition of lam-
ivudine may not be as eﬀective if A181/VT substitutions
compared to N236T substitutions are present. Thus this
combination therapy is not infallible as implied in the
model.
The results are expressed in costs of treatment over a
lifetime, in life years saved and the standardized quality
adjusted life year (QALY) saved. The model identiﬁes
the most eﬃcacious treatment i.e. that which resulted
in the highest number of life years saved and QALYs
gained. Some sensitivity analyses are performed to
examine the eﬀect of diﬀerent parameters on cost-
eﬀectiveness.
In both HBeAg-positive and HBeAg-negative groups
the least expensive strategy was no treatment. The life-
time cost of tenofovir treatment in HBeAg-positive
patients was €87,615 (which rose to €112,585 and
€123,446 depending upon the salvage strategy), and
€105,889 for HBeAg-negative patients. A diﬀerent rank-
ing for the costs of treatment was observed for tenofovir
versus adefovir in HBeAg-negative versus positive
patients. For HBeAg-positive patients, the incremental
cost per QALY was €2426 and €632 versus lamivudine
and no treatment. For HBeAg-negative patients the
incremental cost per QALY with tenofovir was €954
with respect to adefovir dipivoxil, €3949 in relation to
no treatment and €5211 in relation to lamivudine,
respectively. These values are well below the reference
threshold of €20,000–30,000 per QALY recognized by
many public health care systems as the threshold at
which society is willing to pay. Although treatment for
resistance favored tenofovir and entecavir rescue treat-
ment, it is worth pointing out that we do not have wide
experience with this regimen, and its potential long-termtoxicity. Longer term monitoring of osteopaenia in cir-
rhosis, renal impairment and carcinogenesis will be
required.
Hepatitis B remains a numerically important disease
in both endemic and non-endemic areas. In many parts
of Europe, industrialized Asia and the Americas, reim-
bursement for optimal treatment is available. This anal-
ysis of cost-eﬀectiveness validates the current EASL
treatment guidelines, and the role that eﬀective antiviral
treatment has in controlling the disease. The situation is
diﬀerent in many endemic and resource constrained
regions. Treatment is frequently only dispensed to those
who can aﬀord it – a very small minority in many ende-
mic areas. The ﬁnancial burden of treatment remains
unaﬀordable for most.
This health economic model has demonstrated the
cost-eﬀectiveness of tenofovir for the treatment of hep-
atitis B. It is said that the cost of drugs is based on a
premise of what the market will bear, (now tailored to
cost-eﬀectiveness thresholds) rather than being pegged
to recoup research and development costs. It is fortu-
nate that the cost of tenofovir for hepatitis B has prob-
ably been predetermined by the relatively low costs
that were set for the treatment of HIV infection. Ten-
ofovir is being distributed as a generic drug at rela-
tively low cost and little proﬁt, for the treatment of
HIV infection in many African countries. However,
unfortunately the anomaly exists that due to complex
marketing, distribution and sub-licensing agreements,
tenofovir is not currently available for the treatment
of hepatitis B infection in large regions of sub-Saharan
Africa, China and other regions. This situation is to be
decried and will hopefully be urgently corrected by the
responsible industrial partners and government agen-
cies in these regions.References
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